MPPE1 and melanoma: The administration of this cDC1-targeted adjuvant synergizes with mAIM, chemotherapy, or with low dose of TNF, resulting in a regression or a long-lasting protection against melanoma and breast carcinoma in the absence of toxic effects (115).